Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma

Código QR

Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma

Strait et al describe distinct immune microenvironment profiles of responders versus non-responders to combined TGF-β/PD-L1 blockade in mouse models of squamous cell carcinoma (SCC). The results emphasize the potential of combined TGF-β/PD-L1 targeting and provide important clues to guide personaliz...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alexander A. Strait, Rachel A. Woolaver, Spencer C. Hall, Christian D. Young, Sana D. Karam, Antonio Jimeno, Yan Lan, David Raben, Jing H. Wang, Xiao-Jing Wang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/5bc8510595ab4074a4ee88ee8f72c43b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade
por: Guido Kroemer, et al.
Publicado: (2021)

USP12 downregulation orchestrates a protumourigenic microenvironment and enhances lung tumour resistance to PD-1 blockade
por: Zhaojuan Yang, et al.
Publicado: (2021)

Correction: Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
Publicado: (2021)

Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer
por: Grégoire de Streel, et al.
Publicado: (2020)

TGF-β inhibition can overcome cancer primary resistance to PD-1 blockade: A mathematical model.
por: Nourridine Siewe, et al.
Publicado: (2021)

Remodeling of the tumor microenvironment via disrupting Blimp1+ effector Treg activity augments response to anti-PD-1 blockade
por: Michael L. Dixon, et al.
Publicado: (2021)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea M, et al.
Publicado: (2021)

Integrin-αV-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade
por: Ines Malenica, et al.
Publicado: (2021)

Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer
por: Yaohui Gao, et al.
Publicado: (2021)

Neutrophils Extracellular Traps Inhibition Improves PD-1 Blockade Immunotherapy in Colorectal Cancer
por: Hongji Zhang, et al.
Publicado: (2021)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Hyun Tae Lee, et al.
Publicado: (2017)

Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models
por: Chun-Yu Chen, et al.
Publicado: (2017)

Bimodal sensing of guidance cues in mechanically distinct microenvironments
por: Erdem D. Tabdanov, et al.
Publicado: (2018)

EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
por: Li Wang, et al.
Publicado: (2018)

Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy
por: James Harber, et al.
Publicado: (2021)

Silencing of TGF-β1 in tumor cells impacts MMP-9 in tumor microenvironment
por: Lakisha D. Moore-Smith, et al.
Publicado: (2017)

Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer
por: Nitin Roper, et al.
Publicado: (2021)

PD-1 blockade improves the anti-tumor potency of exhausted CD3+CD56+ NKT-like cells in patients with primary hepatocellular carcinoma
por: Longxiang Tao, et al.
Publicado: (2021)

Molecular determinants of response to PD-L1 blockade across tumor types
por: Romain Banchereau, et al.
Publicado: (2021)

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
por: Florie Bertrand, et al.
Publicado: (2017)

Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment
por: Hong Chen, et al.
Publicado: (2021)

Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment
por: Yingxia Zheng, et al.
Publicado: (2020)

Direct and Indirect Effect of TGFβ on Treg Transendothelial Recruitment in HCC Tissue Microenvironment
por: Francesco Dituri, et al.
Publicado: (2021)

Whole-organ analysis of TGF-β-mediated remodelling of the tumour microenvironment by tissue clearing
por: Shimpei I. Kubota, et al.
Publicado: (2021)

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
por: Shohei Koyama, et al.
Publicado: (2016)

Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
por: Darci Phillips, et al.
Publicado: (2021)

Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell carcinoma
por: Patrizia Cammareri, et al.
Publicado: (2016)

TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts
por: Angelo L. Grauel, et al.
Publicado: (2020)

A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity
por: Xia Li, et al.
Publicado: (2020)

Lin−CCR2+ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade
por: Catherine T. Flores, et al.
Publicado: (2018)

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
por: Antoni Ribas, et al.
Publicado: (2020)

Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma
por: Elena Galvani, et al.
Publicado: (2020)

Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation
por: Khashayar Esfahani, et al.
Publicado: (2019)

LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade
por: Yi Liu, et al.
Publicado: (2021)

Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade
por: Victoria Klepsch, et al.
Publicado: (2018)

PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model
por: Neta Rosenzweig, et al.
Publicado: (2019)

Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes
por: Robert A. Szczepaniak Sloane, et al.
Publicado: (2021)

Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy
por: Sara De Biasi, et al.
Publicado: (2021)

Concurrent development of high-stage cutaneous squamous cell carcinoma during complete response of metastatic cutaneous squamous cell carcinoma to programmed cell death protein 1 blockade with cemiplimab
por: Jacob D. Siegel, MD, et al.
Publicado: (2021)

Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis
por: Xiaofei Wang, et al.
Publicado: (2021)